Emory Investigational Drug Service (01021) — Atlanta, Georgia

Emory Investigational Drug Service (01021) is a clinical research site located in Atlanta, Georgia, United States 30322.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

Emory Investigational Drug Service (01021) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: C3G, IC-MPGN, C3 Glomerulopathy.

Sponsors: Apellis Pharmaceuticals, Inc..

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Emory Investigational Drug Service (01021)?

Emory Investigational Drug Service (01021) has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Emory Investigational Drug Service (01021) conducted?

Emory Investigational Drug Service (01021) has 1 clinical trials on record, with 1 currently active. Their work covers C3G, IC-MPGN, C3 Glomerulopathy.

Is Emory Investigational Drug Service (01021) accredited by Crixeo Health?

Emory Investigational Drug Service (01021) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Emory Investigational Drug Service (01021)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.